Pertuzumab Biosimilar – Anti-ERBB2, EGFR2, CD340 mAb – Research Grade

Description of Pertuzumab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb - Research Grade

General information on Anti-ERBB2/EGFR2/CD340(Homo sapiens) (Pertuzumab) Monoclonal Antibody

Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of human epidermal growth factor receptor 2 protein (HER2). It was first used with docetaxel and another HER2-targeting monoclonal antibody trastuzumab to treat metastatic HER2-positive breast cancer. Since then, its indications have been expanded to be used as both neoadjuvant therapy and adjuvant therapy for the treatment of HER2-positive breast cancer with a high risk of recurrence.

Pertuzumab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb binds to Human CD340/ERBB2/HER2 in indirect ELISA Assay

Immobilized CD340 Recombinant Protein (cat. No. PX-P4121) at 0.5µg/mL (100µL/well) can bind Pertuzumab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb (cat. No. PX-TA1058) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 9.566M.

SDS-PAGE for Pertuzumab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb

Pertuzumab Biosimilar - Anti-ERBB2, EGFR2, CD340 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.